Vaxart, Inc.

CIK 0000072444 · FY 2024 · Forensic Intelligence
Forensic
!

Moderate Concern

Multiple indicators suggest areas requiring closer examination. No single test is conclusive, but the pattern warrants further analysis.

Composite Risk
3 / 8
Moderate
Benford's Law
MAD 0.018
Marginally Acceptable
M-Score
-2.04
Grey Zone
Vector Variation
0.14
Low Variation
Red Flags
3
1 High · 2 Medium

Test Results Overview

Test Result Interpretation Status
Benford's Law (MAD) 0.018 First-digit distribution marginally conforms to expected frequencies Marginal
Beneish M-Score -2.04 Score falls in grey zone between manipulation unlikely and likely thresholds Grey Zone
Vector Variation Score 0.14 Financial statement composition changes within normal range Pass
Time-Series Conformity 3 of 5 yrs Three of five historical years show acceptable digit conformity Marginal
Red Flag Triggers 3 flags One high-severity and two medium-severity indicators triggered Flagged

Executive Summary

The forensic analysis of Vaxart, Inc.'s FY 2024 disclosures reveals a pattern of moderate concern across multiple independent tests. The Benford's Law analysis shows a mean absolute deviation of 0.018, placing the company's first-digit distribution at the boundary between conforming and nonconforming. Digits 1 and 5 exhibit statistically significant deviations from expected Benford frequencies, which may indicate selective rounding or estimation clustering in reported figures.

The Beneish M-Score of -2.04 falls within the grey zone, between the -2.22 threshold (below which manipulation is unlikely) and the -1.78 threshold (above which manipulation is likely). The Days Sales in Receivables Index and the Gross Margin Index are the primary contributors driving the score upward. While no single indicator is conclusive, the convergence of a marginally acceptable Benford result, a grey-zone M-Score, and three triggered red flags suggests that Vaxart's financial disclosures merit heightened scrutiny during the review process.

The Vector Variation Score of 0.14 is the sole clearly passing result, indicating that the overall composition of Vaxart's financial statements has not shifted dramatically year-over-year. This suggests that the areas of concern are concentrated in specific line items rather than reflecting a broad restructuring of reported financials.